Log In
BCIQ
Print this Print this
 

ALX-0141

  Manage Alerts
Collapse Summary General Information
Company Ablynx N.V.
DescriptionNanobody against receptor activator of NF-kappa B ligand (RANKL)
Molecular Target Receptor activator of NF-kappa B ligand (RANKL) (TNFSF11)
Mechanism of ActionAntibody; NF-kappa B (NF-kB) inhibitor
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

$2.7M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

10/21/2013

Undisclosed

$2.7M

Undisclosed

Get a free BioCentury trial today